MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Insmed Company Profile (NASDAQ:INSM)

Consensus Ratings for Insmed (NASDAQ:INSM) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $25.33 (151.07% upside)

Analysts' Ratings History for Insmed (NASDAQ:INSM)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Piper Jaffray Cos.Reiterated RatingOverweight$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Citigroup Inc.Lower Price TargetNeutral$21.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Stifel NicolausInitiated CoverageBuy$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Leerink SwannLower Price TargetOutperform$29.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2015Janney Montgomery ScottInitiated CoverageBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Insmed (NASDAQ:INSM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q1($0.52)($0.54)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.49)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q315($0.48)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q2($0.48)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.49)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.56)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.46)($0.54)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.46)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.41)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q413($0.45)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.41)($0.46)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.32)($0.28)$5.38 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.46)($0.43)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.42)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Insmed (NASDAQ:INSM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20161($0.62)($0.62)($0.62)
(Data provided by Zacks Investment Research)
Dividend History for Insmed (NASDAQ:INSM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Insmed (NASDAQ:INSM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/1/2016William LewisCEOBuy50,000$13.34$667,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Donald J. Hayden, Jr.DirectorSell25,000$24.06$601,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015Mark QuigleyVPSell18,750$22.07$413,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Melvin Md SharokyDirectorBuy88,889$11.25$1,000,001.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013William LewisCEOBuy5,233$14.28$74,727.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2013Fmr LlcInsiderSell158,758$12.02$1,908,271.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Fmr LlcInsiderSell310,227$11.49$3,564,508.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Fmr LlcInsiderSell161,531$10.79$1,742,919.49View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2013Fmr LlcInsiderSell146,599$10.01$1,467,455.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Fmr LlcInsiderSell365,779$9.96$3,643,158.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013William LewisCEOBuy7,585$9.83$74,560.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2013Fmr LlcInsiderSell50,000$12.00$600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2013Fmr LlcInsiderSell143,088$12.24$1,751,397.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Fmr LlcInsiderSell85,758$13.00$1,114,854.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2013Fmr LlcInsiderSell130,557$12.85$1,677,657.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2013William LewisCEOBuy9,816$7.58$74,405.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2013William LewisCEOBuy10,770$6.90$74,313.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012William LewisCEOBuy13,568$7.36$99,860.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Insmed (NASDAQ:INSM)
DateHeadline
07/01/16 04:40 PMInsmed, Inc. (NASDAQ:INSM) Earnings Glance and Target Price Review - Engelwood Daily
07/01/16 04:40 PMCovering the Bases on Insmed, Inc. (NASDAQ:INSM): Where is the Stock Going? - Press Telegraph
07/01/16 04:40 PMInsmed, Inc. (NASDAQ:INSM) Expected to Reach Highs Of $35 - Investor Newswire
07/01/16 07:28 AMInsmed Incorporated (NASDAQ:INSM) Shorted Shares Increased 23.32% After Market Selling - Engelwood Daily
06/29/16 07:28 AMCheck on Share Volatility: Insmed Incorporated (NASDAQ:INSM) - Engelwood Daily
06/29/16 07:28 AMWhat Will Happen to Insmed Incorporated Next? The Stock Just Increased A Lot - Engelwood Daily
06/28/16 04:34 PMInfectious Disease Treatment Market in China to Grow at a CAGR of 5.01% During the Period 2016 - 2020; Finds New Report
06/28/16 09:33 AMInvestor News: Insmed Incorporated (NASDAQ:INSM) under Investigation over potential Violations of Securities Laws
06/27/16 04:37 PMInsmed Incorporated (NASDAQ:INSM) Shorted Shares Increased By 23.32% - Press Telegraph
06/24/16 07:18 AMSenzar Asset Management LLC Increased Insmed INC (NASDAQ:INSM) by $4.99 Million as Shares Declined - Engelwood Daily
06/23/16 05:01 PMGrowth Factors Market : Share, Forecast and Demand 2015 – 2021
06/22/16 04:45 PMIMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Insmed, Inc. And Advises Investors With Losses To Contact The Firm - [Business Wire] - Goldberg Law PC announces that it is investigating claims of potential misrepresentations by Insmed, Inc. . The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
06/22/16 04:43 PMInsmed Incorporated : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed, Inc. - INSM
06/22/16 02:34 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Insmed Incorporated - [Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Insmed Incorporated concerning possible violations of federal securities laws.
06/21/16 09:11 AMRecently Issued Stock Ratings For Insmed, Inc. (NASDAQ:INSM) - Fiscal Standard
06/21/16 09:11 AMInsmed Incorporated Stock Momentum Hits Extreme Weakness - CML News
06/19/16 04:14 PMThis Weeks Broker Views For Insmed, Inc. (NASDAQ:INSM) - Fiscal Standard
06/14/16 09:27 AMInvestigation for Investors in Insmed Incorporated (NASDAQ:INSM) over Possible Violations of Securities Laws
06/10/16 04:50 PMJaguar Animal Health (NASDAQ:JAGX) & Insmed Incorporated (NASDAQ:INSM) Stocks to Watch - Wall Street 24
06/10/16 07:26 AMAnalysts Watching Stocks: Novavax, Inc. (NASDAQ:NVAX) , Insmed, Inc. (NASDAQ:INSM) - Street Updates
06/10/16 07:26 AMHC Stocks Broker Alerts: Horizon Pharma PLC (NASDAQ:HZNP), Insmed Incorporated (NASDAQ:INSM) - share market updates (press release)
06/10/16 07:26 AMHome Biotech Stocks Insmed Incorporated | $INSM Stock | Shares Crash Down On Drug Marketing... - TickerTV News (press release)
06/09/16 04:50 PMNotable Stocks in the Spotlight: Agios Pharmaceuticals Inc (NASDAQ:AGIO), Insmed Incorporated (NASDAQ:INSM) - NYSE Journal (press release)
06/09/16 04:50 PMSmall Cap Insmed Incorporated Should Do Better Than MannKind - SmallCap Network
06/09/16 04:50 PMAnalyst Downgrades: QUALCOMM, Inc., Restoration Hardware Holdings Inc, and Insmed Incorporated - Schaeffers Research (blog)
06/09/16 04:50 PMInsmed Incorporated (NASDAQ:INSM) had withdrawn a European marketing application - Inside Trade
06/09/16 04:50 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Insmed Incorporated (INSM) - PR Newswire (press release)
06/09/16 07:23 AMStock Update (NASDAQ:INSM): Insmed Incorporated Announces Withdrawal of Marketing Authorization Application for ... - Smarter Analyst
06/08/16 05:06 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed, Inc. - INSM - [PR Newswire] - NEW YORK, June 8, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed, Inc. ("Insmed" or the Company) (INSM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. On this news, Insmed's share price fell $2.20, or more than 18% to $9.80 in after-hours trading.
06/08/16 04:57 PMForm 8-K INSMED Inc For: Jun 08 - StreetInsider.com
06/08/16 04:09 PMInsmed shares drop after European drug-marketing application withdrawn -
06/08/16 04:03 PMINSMED INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -
06/08/16 03:38 PMInsmed Announces Withdrawal of Marketing Authorization Application for ARIKAYCE™ in Europe - [at noodls] - BRIDGEWATER, N.J., June 08, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that ...
06/04/16 07:22 AMTrending Biotech Stocks Update: TG Therapeutics, Inc. (NASDAQ:TGTX) , Insmed, Inc. (NASDAQ:INSM) - Is stories
06/02/16 04:55 PMSenzar Asset Management LLC Increased Insmed INC (NASDAQ:INSM) by $4.99 Million as Shares Declined - CCH Daily News - Senzar Asset Management LLC Increased Insmed INC (NASDAQ:INSM) by $4.99 Million as Shares DeclinedCCH Daily NewsSenzar Asset Management Llc increased its stake in Insmed Inc (NASDAQ:INSM) by 60.35% based on its latest 2016Q1 regulatory filing with the SEC. Senzar Asset Management Llc bought 415,891 shares as the company's stock declined 26.51% while stock ...and more »
06/02/16 04:55 PMSenzar Asset Management LLC Increased Insmed INC (NASDAQ:INSM) by $4.99 Million as Shares Declined - CCH Daily News - Senzar Asset Management LLC Increased Insmed INC (NASDAQ:INSM) by $4.99 Million as Shares DeclinedCCH Daily NewsSenzar Asset Management Llc increased its stake in Insmed Inc (NASDAQ:INSM) by 60.35% based on its latest 2016Q1 regulatory filing with the SEC. Senzar Asset Management Llc bought 415,891 shares as the company's stock declined 26.51% while stock ...and more »
06/02/16 04:55 PMReview of Price Trends: Insmed, Inc. (NASDAQ:INSM) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates - Review of Price Trends: Insmed, Inc. (NASDAQ:INSM) , PTC Therapeutics, Inc. (NASDAQ:PTCT)Street UpdatesOn 6/1/2016, Insmed, Inc. (NASDAQ:INSM) highlighted upward shift of +0.76% or +0.09 points to $11.89. The company traded a volume of 1.27 million shares over average volume of 390.6 thousand shares. Trailing twelve month period, the firm has earnings ...and more »
06/02/16 04:55 PMReview of Price Trends: Insmed, Inc. (NASDAQ:INSM) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates - Review of Price Trends: Insmed, Inc. (NASDAQ:INSM) , PTC Therapeutics, Inc. (NASDAQ:PTCT)Street UpdatesOn 6/1/2016, Insmed, Inc. (NASDAQ:INSM) highlighted upward shift of +0.76% or +0.09 points to $11.89. The company traded a volume of 1.27 million shares over average volume of 390.6 thousand shares. Trailing twelve month period, the firm has earnings ...and more »
06/01/16 04:03 PMInsmed, Inc. :INSM-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/26/16 10:06 AMUpdated Trading Report: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) , Insmed, Inc. (NASDAQ:INSM) - Street Updates - Updated Trading Report: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) , Insmed, Inc. (NASDAQ:INSM)Street UpdatesOn 5/25/2016, shares of EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) rose +6.588% in trading session and finally closed at $0.631. The company most recent volume stood at 954.68 thousand shares as compared to its average volume of 191.29 ...
05/25/16 11:38 PMInsiders Are Gradually Buying Insmed Incorporated (NASDAQ:INSM) - Wall Street Hints and News - Insiders Are Gradually Buying Insmed Incorporated (NASDAQ:INSM)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Insmed Incorporated (NASDAQ:INSM) have increased their position in the stock by 15.57% over the past 6 months. Insiders now own 0.60% of total outstanding shares. There are both legal and illegal types ...and more »
05/23/16 06:29 PMWere Analysts Bearish Insmed Incorporated (NASDAQ:INSM) This Week? - Wall Street Hints and News - Were Analysts Bearish Insmed Incorporated (NASDAQ:INSM) This Week?Wall Street Hints and NewsOut of 7 analysts covering Insmed (NASDAQ:INSM), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Insmed has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Below is a list of ...Top News: Insmed Incorporated (NASDAQ:INSM), Yingli Green Energy Holding Co. Ltd. (NYSE:YGE), Epizyme, Inc ...KC Registerall 2 news articles »
05/20/16 10:18 AMInsmed Incorporated (NASDAQ:INSM) Sellers Increased By 1.37% Their Shorts - Wall Street Hints and News - Insmed Incorporated (NASDAQ:INSM) Sellers Increased By 1.37% Their ShortsWall Street Hints and NewsThe stock of Insmed Incorporated (NASDAQ:INSM) registered an increase of 1.37% in short interest. INSM's total short interest was 3.96M shares in May as published by FINRA. Its up 1.37% from 3.91M shares, reported previously. With 302,200 shares ...
05/19/16 03:14 PMINSMED INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 11:38 PMRevenue Update on Insmed Incorporated(NASDAQ:INSM) - Trade Calls - Revenue Update on Insmed Incorporated(NASDAQ:INSM)Trade CallsInsmed Incorporated(NASDAQ:INSM) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Earnings per share were $-0.54. Analysts had estimated an EPS of $-0.52. In a different note, On Mar ...
05/09/16 06:38 PMInsmed Incorporated to Present Data on Liposomal Technology To Treat PAH, IPF at 2016 American Thoracic Society ... - Lung Disease News - Lung Disease NewsInsmed Incorporated to Present Data on Liposomal Technology To Treat PAH, IPF at 2016 American Thoracic Society ...Lung Disease NewsARIKAYCE™ (liposomal amikacin for inhalation, or LAI) is an investigational drug comprising the antibiotic amikacin in Insmed's proprietary liposomal technology formulation. ARIKAYCE is being investigated for the treatment of serious lung infections ...
05/09/16 07:08 AMInsmed to Present at the Bank of America Global Healthcare Conference - [at noodls] - BRIDGEWATER, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that ...
05/08/16 07:05 PMAfter Last Week What Do Analysts Think Of Insmed, Inc. (NASDAQ:INSM) - Share Trading News - After Last Week What Do Analysts Think Of Insmed, Inc. (NASDAQ:INSM)Share Trading News03/15/2016 – Stifel Nicolaus began new coverage on Insmed, Inc. giving the company a “buy” rating. They now have a USD 23 price target on the stock. 02/26/2016 – Insmed, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now ...
05/05/16 07:05 PMInsmed Inc.: Insmed Reports First Quarter 2016 Financial Results - The Wall Street Transcript - Insmed Inc.: Insmed Reports First Quarter 2016 Financial ResultsThe Wall Street TranscriptBRIDGEWATER, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the quarter ended March ...and more »
03/02/16 07:00 AMInsmed to Present at the 36th Annual Cowen & Company Healthcare Conference - [GlobeNewswire] - BRIDGEWATER, N.J., March 02, 2016-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that company management will participate ...
About Insmed

Insmed logoInsmed Incorporated is a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients with serious lung diseases. The Company's product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI) is being developed for at least two identified orphan patient populations: patients with non-tuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pseudomonas) lung infections. It is also focused on the development of INS1009, an inhaled treprostinil prodrug. Treprostinil is a prostacyclin used in the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. It has conducted a Phase II clinical trial in the United States and Canada of ARIKAYCE in patients who had treatment-resistant lung infections caused by NTM.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INSM
  • CUSIP:
Key Metrics:
  • Previous Close: $10.09
  • 50 Day Moving Average: $10.85
  • 200 Day Moving Average: $12.92
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $624.34M
  • Current Quarter EPS Consensus Estimate: $-2.21 EPS
Additional Links:
Insmed (NASDAQ:INSM) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha